Get to know our amazingly versatile and unique RVF® technology
Our Products in Action
Multiplo Multiplex Tests
MedMira’s Multiplo multiplex tests include combination testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis.
Miriad Research Tools
Miriad includes toolkits to develop new diagnostic tests and commercialized combination tests.
About MedMira
MedMira is dedicated to improving human health by providing the best in rapid diagnostics. Our patented Rapid Vertical Flow Technology™ delivers fast, accurate results for a range of applications—helping care providers and their patients know more, instantly.
MedMira News >
Message from MedMira’s CEO
In a short time, MedMira has developed an RVF®-based rapid test that detects total antibodies
to the SARS-CoV-2 virus, the causative agent of COVID-19, in human serum, plasma and
venipuncture whole blood. Despite our financial constraints, MedMira, relying solely on our
dedicated team and stakeholders, was able to develop and validate the newest member of our
Reveal family, REVEALCOVID-19™ Total Antibody Test.
MedMira Announces Exclusive Distribution Partnership with Webb Diagnostic Technologies and Initial Order for REVEALCOVID-19™ Total Antibody Test in the U.S.
Halifax, Nova Scotia, 27 May, 2020 – MedMira Inc. (MedMira) (TSXV: MIR) announces that company has entered into an Exclusive Distribution Agreement with Webb Diagnostic Technologies, Inc., (WebbDX) for the distribution of MedMira’s REVEALCOVID-19™ Total Antibody Test. Webb Diagnostic Technologies has placed the first order with the purchase value of approximately CDN$3.5 million. The Company has received the down payment to initiate the production process.
MedMira Announces Progress Update of its REVEALCOVID-19TM Total Antibody test including CE mark
Halifax, Nova Scotia, 21. May, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that it has completed the registration process and affixed the CE mark (Conformité Européene) to its rapid REVEALCOVID-19 TM Total Antibody Test.
MedMira Announces Notification Submission to US FDA Emergency Use Authorization
Halifax, Nova Scotia, April 23, 2020, announced today that it had submitted the notification for the Emergency Use Authorization application offered by the U.S. Food and Drug Administration (FDA) for its newest member of its Reveal line of products for antibody testing.
MedMira Announces Development of COVID-19 Point-of-Care Antibody Test
Halifax, Nova Scotia, April 15, 2020 –MedMira Announces Update on Development of Point-of-Care Antibody Test
MedMira Reports Second Quarter Results
Halifax, Nova Scotia, March 29, 2018 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended January 31, 2018.
MedMira Announces AGM Results and Stock Option Grant
Halifax, Nova Scotia, February 1, 2018 – MedMira Inc. (MedMira) (TSXV: MIR), held its 2018 Annual General Meeting of Shareholders on January 31, 2018 in Halifax, Nova Scotia.
MedMira Reports First Quarter Results
Halifax, Nova Scotia, December 22, 2017 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2017.
©2020 MedMira Inc. All Rights Reserved.